In a statement announcing the go-private transaction, the company said: 'Acquisitions have…been an important part of Alliance's development and the current restrictive funding environment, leverage levels and a number of operational challenges have meant that Alliance has not been able to pursue acquisition opportunities over the past 24 months.'.
SMALL CAP IDEA: Alliance Pharma defects amid shrinking AIM Less than two weeks into 2025 we’ve had our first defection from AIM in the form of Alliance Pharma.
'The Alliance board believes that access to private capital and DBAY's support will allow it to return to its buy-and-build strategy more quickly than if it remained on the public market,' the company said.
In retreating from the junior market after more than 20 years, Alliance, led by Nick Sedgwick, hopes it can kick-start is buy-and-build growth strategy that has been stalled by a lack of access to growth capital.
Goods: Alliance Pharma specialises in consumer healthcare categories with few major competitors, like eczema, scar care and eye health.
